PT - JOURNAL ARTICLE AU - Premkumar, Lakshmanane AU - Segovia-Chumbez, Bruno AU - Jadi, Ramesh AU - Martinez, David R. AU - Raut, Rajendra AU - Markmann, Alena AU - Cornaby, Caleb AU - Bartelt, Luther AU - Weiss, Susan AU - Park, Yara AU - Edwards, Caitlin E. AU - Weimer, Eric AU - Scherer, Erin M. AU - Roupael, Nadine AU - Edupuganti, Sri AU - Weiskopf, Daniela AU - Tse, Longping V. AU - Hou, Yixuan J. AU - Margolis, David AU - Sette, Alessandro AU - Collins, Matthew H. AU - Schmitz, John AU - Baric, Ralph S. AU - de Silva, Aravinda M. TI - The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies AID - 10.1101/2020.05.06.20093377 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.06.20093377 4099 - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093377.short 4100 - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093377.full AB - A new Severe Acute Respiratory Syndrome Coronavirus variant (SARS-CoV-2) that first emerged in late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this highly contagious virus present with clinically inapparent, mild or severe disease. Currently, the presence of the virus in individual patients and at the population level is being monitored by testing symptomatic cases by PCR for the presence of viral RNA. There is an urgent need for SARS-CoV-2 serologic tests to identify all infected individuals, irrespective of clinical symptoms, to conduct surveillance and implement strategies to contain spread. As the receptor binding domain (RBD) of the viral spike (S) protein is poorly conserved between SARS-CoVs and other pathogenic human coronaviruses, the RBD represents a promising antigen for detecting CoV specific antibodies in people. Here we use a large panel of human sera (70 SARS-CoV-2 patients and 71 control subjects) and hyperimmune sera from animals exposed to zoonotic CoVs to evaluate the performance of the RBD as an antigen for accurate detection of SARS-CoV-2-specific antibodies. By day 9 after the onset of symptoms, the recombinant SARS-CoV-2 RBD antigen was highly sensitive (98%) and specific (100%) to antibodies induced by SARS-CoVs. We observed a robust correlation between levels of RBD binding antibodies and SARS-CoV-2 neutralizing antibodies in patients. Our results, which reveal the early kinetics of SARS-CoV-2 antibody responses, strongly support the use of RBD-based antibody assays for population-level surveillance and as a correlate of neutralizing antibody levels in people who have recovered from SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the University of North Carolina School of Medicine (PL and AD), National Institutes of Health contract Nr. 75N9301900065 (A.S. and D.W.), NIH NIAID T32 AI007151 (DM) and a Burroughs Welcome Fund Postdoctoral Enrichment Program Award (DM).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAntigens are available under an MTA. Please contact Lakshmanane Premkumar (prem@med.unc.edu) or Aravinda M. de Silva (aravinda_desilva@med.unc.edu)